

LIST OF TABLES

Table		Page
(1)	Comparison between different studied groups according to demographic data.	26
(2)	Comparison between the different studied groups according to presenting signs and symptoms.	27
(3)	Comparison between the different studied groups according to clinical examination parameters.	28
(4)	Comparison between the different studied groups according to CBC findings	29
(5)	Comparison between the different studied groups according to liver function.	30
(6)	Comparison between different studied groups according to severity of liver disease (child-pugh classification).	31
(7)	Distribution of BCLC staging system in HCC patients (n = 21).	33
(8)	Comparison between the different studied groups according to alpha-feto protein (AFP).	34
(9)	Comparison between the different studied groups according to clusterin levels.	36
(10)	Diagnostic performance of AFP and clusterin in HCC group against HCV positive patient with and without cirrhosis.	39
(11)	Diagnostic performance of AFP alone, clusterin alone and AFP and clusterin in combination in HCC group against HCV positive patient with cirrhosis.	40
(12)	Diagnostic performance of AFP alone, clusterin alone and AFP and clusterin in combination in HCC group against HCV positive patients with and without cirrhosis.	41
(13)	Correlation between serum clusterin level on one hand and AFP, child score, BCLC staging on the other hand.	42
(14)	Correlation between serum clusterin level on one hand and presenting signs, symptoms and clinical examination on the other hand.	42
(15)	Correlation between serum clusterin level on one hand and laboratory findings in HCC patients (Group III) on the other hand.	43
(16)	Relation between serum clusterin level on one hand and BCLC staging system with its criteria in HCC patients (Group III) on the other hand.	44
(17)	Relation between serum AFP level on one hand and BCLC staging with its criteria in HCC patients (Group III) on the other hand.	45

LIST OF FIGURES

Figure		Page
(1)	Mechanisms of clusterin action.	11
(2)	Standard curve of clusterin.	21
(3)	Comparison between the different studied groups according to presenting signs and symptoms.	27
(4)	Comparison between the different studied groups according to clinical examination parameters.	28
(5)	Comparison between different studied groups according to severity of liver disease (child-pugh classification).	32
(6)	Mean values of serum AFP in the different studied groups.	35
(7)	Mean values of serum clusterin levels in different studied groups.	37
(8)	ROC curve for the diagnostic performance of AFP and clusterin to diagnose HCC cases.	39
(9)	ROC curve for the diagnostic performance of AFP alone, clusterin alone and AFP and clusterin in combination in HCC group against HCV positive patients with cirrhosis.	40
(10)	ROC curve for the diagnostic performance of AFP alone, clusterin alone and AFP and clusterin in combination in HCC group against HCV positive patients with and without cirrhosis.	41

LIST OF ABBREVIATION

AASLD	: American association for the study of liver diseases
AFB1	: Aflatoxin B1
AFP	: Alpha-feto protein
AFP-L3	: Lens culinaris agglutinin-reactive fraction of AFP
AFU	: Alpha-L-fucosidase
ALT	: Alanine amino transferase
ALP	: Alkaline phosphatase
APOJ	: Apolipoprotein J
AST	: Aspartate amino transferase
ASO	: Antisense oligonucleotides
AUC	: Area under curve
BCLC	: Barcelona clinic liver cancer
BMI	: Body mass index
CC	: Cholangiocarcinoma
CLU	: Clusterin
CT	: Computed tomography
EASL	: European association for the study of the liver
EDTA	: Ethelenediamine tetra-acetic acid
ELISA	: Enzyme-linked immunosorbent assay
ER	: Endoplasmic reticulum
GGT	: Gamma Glutamyl Transferase
GIT	: Gastrointestinal tract
Hb	: Hemoglobin
HBV	: Hepatitis B virus
HB_sAg	: Hepatitis B surface antigen
HCC	: Hepatocellular carcinoma
HCV	: Hepatitis C virus
HGF	: Hepatocyte growth factor
IFN	: Interferon
IGF-1	: Insulin-like growth factor
LN	: Lymph node
MRI	: Magnetic resonance imaging
NAFLD	: Non-alcoholic fatty liver disease
NASH	: Non-alcoholic steatohepatitis
_nCLU	: Nuclear clusterin
NPV	: Negative predictive value
NSCLC	: Non-small-cell lung cancer
PCT	: Porphyria cutanea tarda
PEI	: Percutaneous ethanol injection
PIVKA II	: Prothrombin induced by vitamin K absence II

PI3K	: Phosphatidylinositol 3- kinase
PKB	: Protein kinase B
pnCLU	: Non-glycosylated protein precursor of clusterin
PPV	: Positive predictive value
psCLU	: Presecretory clusterin
PS	: Performance status
PT	: Prothrombin time
RFA	: Radiofrequency ablation
ROC	: Receiver operating characteristics
sCLU	: Secretory clusterin
SGP2	: Sulfated glycoprotein 2
siRNA	: Small interfering RNA
SST	: Serum separator tube
TACE	: Transarterial chemoembolization
TRPM2	: Testosterone-repressed prostate message 2
US	: Ultrasound
VEGF	: Vascular endothelial growth factor
VIP	: Vasoactive intestinal peptide
WBC_s	: White blood cells